Katja Häkkinen

Ms. Katja Häkkinen

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2022 in The Pharmacogenomics Journal
Verified
Journal Article
Open access
PDF file
KHKatja Häkkinen
Katja Häkkinen
JKJohanna I. Kiiski
Johanna I. Kiiski
MLMarkku Lähteenvuo
Markku Lähteenvuo
TJTuomas Jukuri
Tuomas Jukuri
KSKimmo Suokas
Kimmo Suokas
AAAri V. Ahola-Olli
Ari V. Ahola-Olli
We demonstrate that CYP2D6 copy-number variation (CNV) can be imputed using existing imputation algorithms. Additionally, we report frequencies of key pharmacogenetic variants in individuals with a psychotic disorder from the genetically bottle-necked population of Finland. We combined GWAS chip and CYP2D6 CNV data from the Breast Cancer Pain Genetics study to construct an imputation panel (n = 902) for CYP2D6 CNV. The resulting data set was used as a CYP2D6 CNV imputation panel in 9262 non-related individuals from the SUPER-Finland study. Based on imputation of 9262 individuals we confirm the higher frequency of CYP2D6 ultrarapid metabolizers and a 22-fold enrichment of the UGT1A1 decreased function variant rs4148323 (UGT1A1*6) in Finland compared with non-Finnish Europeans. Similarly, the NUDT15 variant rs116855232 was highly enriched in Finland. We demonstrate that imputation of CYP2D6 CNV is possible and the methodology enables studying CYP2D6 in large biobanks with genome-wide data.

23 May 2021 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Atiqul MazumderAtiqul Mazumder
Atiqul Mazumder
JBJennifer Barnett
Jennifer Barnett
NLNina Lindberg
Nina Lindberg
MTMinna Torniainen-Holm
Minna Torniainen-Holm
MLMarkku Lähteenvuo
Markku Lähteenvuo
JVJuha Veijola
Juha Veijola
The purpose of this study was to explore the association between cognition and hazardous drinking and alcohol use disorder in schizophrenia and schizoaffective disorder. Cognition is more or less compromised in schizophrenia, and schizoaffective disorder and alcohol use might aggravate this phenomenon. The study population included 3362 individuals from Finland with diagnoses of schizophrenia or schizoaffective disorder. Hazardous drinking was screened with the AUDIT-C (Alcohol Use Disorders Identification Test for Consumption) screening tool. Alcohol use disorder (AUD) diagnoses were obtained from national registrar data. Participants performed two computerized tasks from the Cambridge Automated Neuropsychological Test Battery (CANTAB) on a tablet computer: The Five-Choice Serial Reaction Time Task (5-CSRTT) or the reaction time (RT) test and the Paired Associative Learning (PAL) test. The association between alcohol use and the RT and PAL tests was analyzed with log-linear regression and logistic regression, respectively. After adjustment for age, education, housing status, and the age at which the respondents had their first psychotic episodes, hazardous drinking was associated with a lower median RT in females and less variable RT in males, while AUD was associated with a poorer PAL test performance in terms of the total errors adjusted scores (TEASs) in females. Our findings of positive associations between alcohol and cognition in schizophrenia and schizoaffective disorder are unique.

13 February 2023 in Molecular Pharmaceutics
Verified
Journal Article
Open access
KHKatja Häkkinen
Katja Häkkinen
WKWilma Kiander
Wilma Kiander
HKHeidi Kidron
Heidi Kidron
MLMarkku Lähteenvuo
Markku Lähteenvuo
LULea Urpa
Lea Urpa
MNMikko Niemi
Mikko Niemi
Variants in the SLCO1B1 (solute carrier organic anion transporter family member 1B1) gene encoding the OATP1B1 (organic anion transporting polypeptide 1B1) protein are associated with altered transporter function that can predispose patients to adverse drug effects with statin treatment. We explored the effect of six rare SLCO1B1 single nucleotide variants (SNVs) occurring in Finnish individuals with a psychotic disorder on expression and functionality of the OATP1B1 protein. The SUPER-Finland study has performed exome sequencing on 9381 individuals with at least one psychotic episode during their lifetime. SLCO1B1 SNVs were annotated with PHRED-scaled combined annotation-dependent (CADD) scores and the Ensembl variant effect predictor. In vitro functionality studies were conducted for the SNVs with a PHRED-scaled CADD score of >10 and predicted to be missense. To estimate possible changes in transport activity caused by the variants, transport of 2 ',7 '-dichlorofluorescein (DCF) in OATP1B1-expressing HEK293 cells was measured. According to the findings, additional tests with rosuvastatin and estrone sulfate were conducted. The amount of OATP1B1 in crude membrane fractions was quantified using a liquid chromatography tandem mass spectrometry-based quantitative targeted absolute proteomics analysis. Six rare missense variants of SLCO1B1 were identified in the study population, located in transmembrane helix 3: c.317T>C (p.106I>T), intracellular loop 2: c.629G>T (p.210G>V), c.633A>G (p.211I>M), c.639T>A (p.213N>L), transmembrane helix 6: 820A>G (p.274I>V), and the C-terminal end: 2005A>C (p.669N>H). Of these variants, SLCO1B1 c.629G>T (p.210G>V) resulted in the loss of in vitro function, abolishing the uptake of DCF, estrone sulfate, and rosuvastatin and reducing the membrane protein expression to 31% of reference OATP1B1. Of the six rare missense variants, SLCO1B1 c.629G>T (p.210G>V) causes a loss of function of OATP1B1 transport in vitro and severely decreases membrane protein abundance. Carriers of SLCO1B1 c.629G>T might be susceptible to altered pharmacokinetics of OATP1B1 substrate drugs and might have increased likelihood of adverse drug effects such as statin-associated musculoskeletal symptoms.

30 August 2021 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Atiqul MazumderAtiqul Mazumder
Atiqul Mazumder
JBJennifer Barnett
Jennifer Barnett
EIErkki Tapio Isometsä
Erkki Tapio Isometsä
NLNina Lindberg
Nina Lindberg
MTMinna Torniainen-Holm
Minna Torniainen-Holm
JVJuha Veijola
Juha Veijola
The purpose of this study was to explore the association of cognition with hazardous drinking and alcohol-related disorder in persons with bipolar disorder (BD). The study population included 1268 persons from Finland with bipolar disorder. Alcohol use was assessed through hazardous drinking and alcohol-related disorder including alcohol use disorder (AUD). Hazardous drinking was screened with the Alcohol Use Disorders Identification Test for Consumption (AUDIT-C) screening tool. Alcohol-related disorder diagnoses were obtained from the national registrar data. Participants performed two computerized tasks from the Cambridge Automated Neuropsychological Test Battery (CANTAB) on A tablet computer: the 5-choice serial reaction time task, or reaction time (RT) test and the Paired Associative Learning (PAL) test. Depressive symptoms were assessed with the Mental Health Inventory with five items (MHI-5). However, no assessment of current manic symptoms was available. Association between RT-test and alcohol use was analyzed with log-linear regression, and eβ with 95% confidence intervals (CI) are reported. PAL first trial memory score was analyzed with linear regression, and β with 95% CI are reported. PAL total errors adjusted was analyzed with logistic regression and odds ratios (OR) with 95% CI are reported. After adjustment of age, education, housing status and depression, hazardous drinking was associated with lower median and less variable RT in females while AUD was associated with a poorer PAL test performance in terms of the total errors adjusted scores in females. Our findings of positive associations between alcohol use and cognition in persons with bipolar disorder are difficult to explain because of the methodological flaw of not being able to separately assess only participants in euthymic phase.

27 October 2021 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Atiqul MazumderAtiqul Mazumder
Atiqul Mazumder
JBJennifer Barnett
Jennifer Barnett
EIErkki Tapio Isometsä
Erkki Tapio Isometsä
NLNina Lindberg
Nina Lindberg
MTMinna Torniainen-Holm
Minna Torniainen-Holm
JVJuha Veijola
Juha Veijola
The purpose of this study was to explore the association of cognition with hazardous drinking Polygenic Scores (PGS) in 2649 schizophrenia, 558 schizoaffective disorder, and 1125 bipolar disorder patients in Finland. Hazardous drinking PGS was computed using the LDPred program. Participants performed two computerized tasks from the Cambridge Automated Neuropsychological Test Battery (CANTAB) on a tablet computer: the 5-choice serial reaction time task, or Reaction Time (RT) test, and the Paired Associative Learning (PAL) test. The association between hazardous drinking PGS and cognition was measured using four cognition variables. Log-linear regression was used in Reaction Time (RT) assessment, and logistic regression was used in PAL assessment. All analyses were conducted separately for males and females. After adjustment of age, age of onset, education, household pattern, and depressive symptoms, hazardous drinking PGS was not associated with reaction time or visual memory in male or female patients with schizophrenia, schizoaffective, and bipolar disorder.

10 August 2022 in medRxiv
Verified
Preprint
Open access
PDF file
KHKatja Häkkinen
Katja Häkkinen
WKWilma Kiander
Wilma Kiander
HKHeidi Kidron
Heidi Kidron
MLMarkku Lähteenvuo
Markku Lähteenvuo
LULea Urpa
Lea Urpa
TAThe Super-Finland Researchers Listed In The Acknowledgements
The Super-Finland Researchers Listed In The Acknowledgements
Aim: Variants in the SLCO1B1 (solute carrier organic anion transporter family member 1B1) gene encoding the OATP1B1 (organic anion transporting polypeptide 1B1) protein are associated with altered transporter function that can predispose patients to adverse drug effects with statin treatment. We explored the effect of six rare SLCO1B1 single nucleotide variants (SNVs) occurring in Finnish individuals with a psychotic disorder on expression and functionality of the OATP1B1 protein. Methods: The SUPER-Finland study has performed exome sequencing on 9,381 individuals with at least one psychotic episode during their lifetime. SLCO1B1 SNVs were annotated with PHRED-scaled Combined Annotation-Dependent (CADD) scores and the Ensembl variant effect predictor (VEP). In vitro functionality studies were conducted for the SNVs with PHRED-scaled CADD score >10 and predicted to be missense. To estimate possible changes in transport activity caused by the variants, transport of 2’,7’-dichlorofluorescein (DCF) in OATP1B1 expressing HEK293 cells was measured. The amount of OATP1B1 in crude membrane fractions was quantified with a LC–MS/MS-based quantitative targeted absolute proteomics analysis. Results: Six rare missense variants of SLCO1B1 were identified in the study population located in transmembrane helix 3: c.317T>C (p.106I>T), intracellular loop 2: c.629G>T (p.210G>V), c.633A>G (p.211I>M), c.639T>A (p.213N>L), transmembrane helix 6: 820A>G (p.274I>V), and the C-terminal end: 2005A>C (p.669N>H). Of these variants, SLCO1B1 c.629G>T (p.210G>V) resulted in protein loss of function, abolishing the uptake of DCF and reducing membrane protein expression to 31% of reference OATP1B1. Conclusions: Of the six rare missense variants, SLCO1B1 c.629G>T (p.210G>V) causes loss-of-function of OATP1B1 transport and severely decreases membrane protein abundance. Carriers of SLCO1B1 c.629G>T may be susceptible to altered pharmacokinetics of OATP1B1 substrate drugs and may have increased likelihood of adverse drug effects such as statin-associated musculoskeletal symptoms. Abstract Figure: